<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/68D0E3C9-9246-4CFC-B5E9-48584CF82993"><gtr:id>68D0E3C9-9246-4CFC-B5E9-48584CF82993</gtr:id><gtr:name>University of Manchester</gtr:name><gtr:department>Medical and Human Sciences</gtr:department><gtr:address><gtr:line1>Oxford Road</gtr:line1><gtr:city>Manchester</gtr:city><gtr:postCode>M13 9PL</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/68D0E3C9-9246-4CFC-B5E9-48584CF82993"><gtr:id>68D0E3C9-9246-4CFC-B5E9-48584CF82993</gtr:id><gtr:name>University of Manchester</gtr:name><gtr:address><gtr:line1>Oxford Road</gtr:line1><gtr:city>Manchester</gtr:city><gtr:postCode>M13 9PL</gtr:postCode><gtr:region>North West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/39E56457-067D-4283-BBC3-AA8D686401F3"><gtr:id>39E56457-067D-4283-BBC3-AA8D686401F3</gtr:id><gtr:firstName>Richard</gtr:firstName><gtr:surname>Warren</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0500449"><gtr:id>822ECE46-04FE-4437-B06D-7960C0877474</gtr:id><gtr:title>Optimising methotrexate therapy for psoriasis - a pharmacogenetic study.</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Fellowship</gtr:grantCategory><gtr:grantReference>G0500449</gtr:grantReference><gtr:abstractText>Psoriasis is a chronic, currently incurable skin disease that affects 2% of the UK population and leads to profound psychosocial disability. Twenty percent of psoriasis patients have severe disease which requires systemic therapy with drugs such as methotrexate but response is unpredictable and there is concern about serious toxicity to liver and bone marrow. Strategies to optimise safe and effective prescribing of methotrexate have been neglected, particularly given the fact that there are genetic differences in how individuals metabolise this drug. Work performed in patients with rheumatoid arthritis and in organ transplant patients has linked these genetic differences to both clinical response and side-effects from the drug; it is unknown if the same is true in psoriasis. It is possible to analyse these genetic differences from blood samples. In addition, it is known that patients with psoriasis get liver toxicity more frequently than patients taking methotrexate for other conditions, this may be due to increased levels of a chemical called homocysteine. I will measure levels of homocysteine in blood and then correlate these to look for an association. It is very likely methotrexate will be a mainstay of severe psoriasis treatment for many years, we aim to optimise its use.</gtr:abstractText><gtr:technicalSummary>Psoriasis is a chronic, currently incurable skin disease that affects 2% of the UK population and leads to profound psychosocial disability. Twenty percent of psoriasis patients have severe disease which requires systemic therapy with drugs such as methotrexate (MTX), however response is unpredictable. Similarly there is concern about unpredictable and serious toxicity to liver and bone marrow. Strategies to optimise safe and effective prescribing of MTX have been neglected, particularly given the fact that significant single nucleotide polymorphisms (SNPs) exist in its metabolic pathway. Work performed in patients with Rheumatoid arthritis (RA) and in organ transplant patients has produced important data linking both efficacy and toxicity to the presence of some of these SNPs. Objectives: To establish if SNPs in enzymes involved in metabolic pathways associated with MTX determine its efficacy and toxicity when used as therapy for psoriasis. To define if homocysteine plays a role in MTX related toxicities and how folate supplementation may influence this. Genetic Studies: A large cohort of psoriasis patients who have received MTX are available in Manchester with good clinical data to investigate the major known SNPs in enzymes and transporters of the folate pathway relevant to the metabolism of MTX. These SNPs will be linked to the clinical response of MTX therapy and major toxicities eg hepatotoxicity. It is believed that one mechanism of action of MTX in psoriasis is via targeting T-cell-function. MTX inhibits aminoimadazolecarboxamide ribotide transformylase leading to accumulation of intracellular adenosine which is toxic to T cells. I will attempt to correlate SNPs in this enzyme to efficacy. Clinical Studies: Homocysteine has been implicated in hepatotoxicity in RA patients treated with MTX. I will assess homocysteine levels in blood of psoriasis patients treated either with MTX alone or MTX supplemented by folic acid to ascertain whether folate replacement in these patients reduces blood levels of homocysteine. Anecdotally patients with psoriasis are more susceptible to MTX-induced hepatotoxicity than patients with rheumatoid arthritis. Using extensive databases available in Manchester I will assess whether these are evidence based observations. The project is well placed to succeed in that Professor Griffiths heads the north-west regional psoriasis clinic in Manchester catering for patients with severe disease. Dr Worthington of the Arthritis and Rheumatism Council Epidemiology Unit (ARC-EU) in Manchester is an acknowledged expert in immunogenetics and has a successful collaboration with Professor Griffiths on a variety of projects investigating SNPs in pathways relevant to psoriasis.</gtr:technicalSummary><gtr:fund><gtr:end>2008-08-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2005-09-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>165663</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>King's College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>School of Medicine KCL</gtr:department><gtr:description>Pharmacogenetic projects</gtr:description><gtr:id>E112097E-BF97-48FB-9D34-FF0A00CFD2B2</gtr:id><gtr:impact>in progress</gtr:impact><gtr:outcomeId>UsKzFQ3vDd5-1</gtr:outcomeId><gtr:partnerContribution>setting up a national pharmacogenetic project in dermatology</gtr:partnerContribution><gtr:piContribution>one of 3 mains centres providing clinical data / joint proposal for further funding. A PhD student under my supervision will work on this study</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Podcast in United States</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:id>CAF9F063-327C-4B5C-A5F4-A8DD030441BA</gtr:id><gtr:impact>podcast for patients involved in the texas Dermatology Assocation

Awaited, just gone live</gtr:impact><gtr:outcomeId>8F1D8AC6300</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>media briefing</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:id>A24E50E1-D7AF-4567-98AC-605E2C74F23F</gtr:id><gtr:impact>I was invited to attend and give and overview of pharmacogenetics in dermatology at the media briefing at the European Academy of Dermatology and Venereology annual meeting. This was a result of being an invited plenary speaker at this meeting where data from my PhD formed a large part of the plenary session.

dissemination of the work at major european congress.

Potential European colloborations</gtr:impact><gtr:outcomeId>UX1HBncWxnS</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>General Practioner Journals</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:id>EC7362B0-BD0A-463B-8046-D7EC4D9AEA2B</gtr:id><gtr:impact>publictaion in GP journal

Significant interest from primary care about modifying drug use</gtr:impact><gtr:outcomeId>33BE1AAA8D0</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2007</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>64F8A556-BD24-429D-A9C9-7327795BE33C</gtr:id><gtr:title>Topical treatments for scalp psoriasis.</gtr:title><gtr:parentPublicationTitle>Drugs</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a1481130242ab0bfe944e07f529226f8"><gtr:id>a1481130242ab0bfe944e07f529226f8</gtr:id><gtr:otherNames>Warren RB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0012-6667</gtr:issn><gtr:outcomeId>doi_55f983983ab389b2</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>64621E7E-565A-457F-96B2-4F115EDDCF78</gtr:id><gtr:title>Systemic therapies for psoriasis: methotrexate, retinoids, and cyclosporine.</gtr:title><gtr:parentPublicationTitle>Clinics in dermatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a1481130242ab0bfe944e07f529226f8"><gtr:id>a1481130242ab0bfe944e07f529226f8</gtr:id><gtr:otherNames>Warren RB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0738-081X</gtr:issn><gtr:outcomeId>C4D7A4E089C</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7AD22848-FA65-4763-864D-9509692D7573</gtr:id><gtr:title>Methotrexate for psoriasis in the era of biological therapy.</gtr:title><gtr:parentPublicationTitle>Clinical and experimental dermatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a1481130242ab0bfe944e07f529226f8"><gtr:id>a1481130242ab0bfe944e07f529226f8</gtr:id><gtr:otherNames>Warren RB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0307-6938</gtr:issn><gtr:outcomeId>14B18BDBB18</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>428126CA-FD64-4597-AC43-701865ED885E</gtr:id><gtr:title>No association between polymorphisms in the interleukin-15 gene and early-onset psoriasis in a UK cohort suggests heterogeneity for this susceptibility locus identified in Chinese psoriasis patients.</gtr:title><gtr:parentPublicationTitle>The Journal of investigative dermatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2c6d7c9acf9f7cb5a15496246b801e1a"><gtr:id>2c6d7c9acf9f7cb5a15496246b801e1a</gtr:id><gtr:otherNames>Smith RL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0022-202X</gtr:issn><gtr:outcomeId>A5056C516FB</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A97D67C2-D978-4974-A3C0-90DD21924365</gtr:id><gtr:title>Outcomes of methotrexate therapy for psoriasis and relationship to genetic polymorphisms.</gtr:title><gtr:parentPublicationTitle>The British journal of dermatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a1481130242ab0bfe944e07f529226f8"><gtr:id>a1481130242ab0bfe944e07f529226f8</gtr:id><gtr:otherNames>Warren RB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0007-0963</gtr:issn><gtr:outcomeId>24C9BA89B0B</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0A7ABF5E-73CE-4E10-8F47-09CFAC0206C9</gtr:id><gtr:title>Identification of ZNF313/RNF114 as a novel psoriasis susceptibility gene.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2f2e4ca853cd65895743353f76fa758a"><gtr:id>2f2e4ca853cd65895743353f76fa758a</gtr:id><gtr:otherNames>Capon F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn><gtr:outcomeId>97F91B0A41C</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C05FCA69-9D7E-438C-BA57-ED815030A58F</gtr:id><gtr:title>Biologic therapies for psoriasis: practical experience in a U.K. tertiary referral centre.</gtr:title><gtr:parentPublicationTitle>The British journal of dermatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a1481130242ab0bfe944e07f529226f8"><gtr:id>a1481130242ab0bfe944e07f529226f8</gtr:id><gtr:otherNames>Warren RB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0007-0963</gtr:issn><gtr:outcomeId>0850D050E80</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B6CCAA9B-1388-431A-BE8D-CC1D4AE81AC1</gtr:id><gtr:title>Medical dermatology.</gtr:title><gtr:parentPublicationTitle>Clinical medicine (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a1481130242ab0bfe944e07f529226f8"><gtr:id>a1481130242ab0bfe944e07f529226f8</gtr:id><gtr:otherNames>Warren RB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1470-2118</gtr:issn><gtr:outcomeId>6D0010A630D</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>46714C1E-B7A7-4792-8E22-B85258853B04</gtr:id><gtr:title>Polymorphisms in the IL-12beta and IL-23R genes are associated with psoriasis of early onset in a UK cohort.</gtr:title><gtr:parentPublicationTitle>The Journal of investigative dermatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2c6d7c9acf9f7cb5a15496246b801e1a"><gtr:id>2c6d7c9acf9f7cb5a15496246b801e1a</gtr:id><gtr:otherNames>Smith RL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0022-202X</gtr:issn><gtr:outcomeId>A0DF5711C6F</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8F8D91F7-1607-48F0-96CB-9ECBC66EA0C8</gtr:id><gtr:title>Genetic variation in efflux transporters influences outcome to methotrexate therapy in patients with psoriasis.</gtr:title><gtr:parentPublicationTitle>The Journal of investigative dermatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a1481130242ab0bfe944e07f529226f8"><gtr:id>a1481130242ab0bfe944e07f529226f8</gtr:id><gtr:otherNames>Warren RB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0022-202X</gtr:issn><gtr:outcomeId>83868442232</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8F397B99-BEF4-4EB5-B8F1-6B66368B5864</gtr:id><gtr:title>What's new in psoriasis? Analysis of the clinical significance of systematic reviews on psoriasis published in 2007 and 2008.</gtr:title><gtr:parentPublicationTitle>Clinical and experimental dermatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/91bbb357d33447809f83d82813c0c85c"><gtr:id>91bbb357d33447809f83d82813c0c85c</gtr:id><gtr:otherNames>Brown BC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0307-6938</gtr:issn><gtr:outcomeId>54806eeb87a573.39154435</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BD8BAA46-EC0E-469C-9AC9-498D2207C224</gtr:id><gtr:title>Polymorphisms in the PTPN22 region are associated with psoriasis of early onset.</gtr:title><gtr:parentPublicationTitle>The British journal of dermatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2c6d7c9acf9f7cb5a15496246b801e1a"><gtr:id>2c6d7c9acf9f7cb5a15496246b801e1a</gtr:id><gtr:otherNames>Smith RL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0007-0963</gtr:issn><gtr:outcomeId>8D42F3F17FD</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>75C6D0DD-1B4A-46B3-B7E1-A7401CD1F5F5</gtr:id><gtr:title>Genetic susceptibility to psoriasis: an emerging picture.</gtr:title><gtr:parentPublicationTitle>Genome medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2c6d7c9acf9f7cb5a15496246b801e1a"><gtr:id>2c6d7c9acf9f7cb5a15496246b801e1a</gtr:id><gtr:otherNames>Smith RL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1756-994X</gtr:issn><gtr:outcomeId>BF5F04BC6DF</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0500449</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7EE9741E-CF94-420A-B0AB-A7811523CF2C</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Skin</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>7135039D-2DB0-4D41-87B3-FA1C8D38E133</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>6.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>